WASHINGTON, D.C. – A blood test designed to help identify signs of Alzheimer’s disease could provide doctors with a less invasive option for evaluating patients experiencing memory problems.

The test measures biomarkers associated with amyloid plaques in the brain, a key characteristic of Alzheimer’s disease.

Traditionally, doctors have relied on specialized brain imaging or spinal fluid testing to help identify Alzheimer’s-related changes. Blood testing could reduce the need for some of those procedures.

The Food and Drug Administration has authorized blood tests for use in evaluating patients with symptoms of cognitive decline, including tests intended for adults ages 55 and older.

Research involving one recently cleared test found that results agreed with brain imaging findings in approximately 88% of patients with cognitive impairment and 91% of those without cognitive impairment.

The FDA emphasizes that blood test results should be evaluated alongside a patient’s medical history, symptoms and other assessments, including cognitive testing.

The tests are not intended to serve as stand-alone screening tools for people without symptoms, but could help physicians determine whether additional Alzheimer’s testing is necessary.